Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp.
Imiquimod 3.75% cream is a topical formulation of imiquimod intended for daily application to treat actinic keratoses of the entire face or balding scalp. The objective of the study was to characterize serum imiquimod and metabolite pharmacokinetics. Nineteen subjects with actinic keratoses applied two packets of imiquimod 3.75% cream (18.75 mg imiquimod total) once daily for 21 days to a treatment area approximately 200 cm(2) in size on the face and/or balding scalp. Blood samples were obtained prior to application of doses 1, 7, 14 and 21, and at selected timepoints after application of doses 1 and 21. After multiple dosing (day 21) serum imiquimod mean C (max) was 0.323 (standard deviation 0.159) ng/mL, mean AUC(0-24) 5.974 (3.088) ng h/mL, and mean T(1/2) 29.3 (17.0) h. Steady-state was achieved by day 14; multiple dose accumulation ratios were 2.8 based on imiquimod C (max) and 3.9 based on AUC. Serum concentrations of imiquimod metabolites were only sporadically quantifiable in three subjects. One subject discontinued from study for adverse events of body aches and fatigue that were attributed to study drug. Treatment-related adverse events occurred in 42.1% (8/19) of the subjects. Systemic imiquimod exposure, as reflected by serum drug concentration, was low after daily application of two packets of imiquimod 3.75% cream for 21 days. Steady state was achieved by day 14, and the observed half-life of approximately 29 h supports daily dosing of the product.
Kulp
James
J
Graceway Pharmaceuticals LLC, Exton, PA 19341, USA.
Levy
Sharon
S
Fein
Melanie C
MC
Adams
Michael
M
Furst
John
J
Meng
Tze-Chiang
TC
D000368:Aged; D000369:Aged, 80 and over; D000505:Alopecia; D000634:Aminoquinolines / Q000097:blood / Q000493:pharmacokinetics*; D005145:Face / Q000473:pathology*; D005260:Female; D006207:Half-Life; D006801:Humans; D000077271:Imiquimod; D055623:Keratosis, Actinic / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012535:Scalp / Q000473:pathology*; D012867:Skin / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
D000634:Aminoquinolines; D000077271:Imiquimod